3399 - Stereotactic Body Radiation Therapy with PD-1 Inhibitor for Locally Advanced or Locoregionally Recurrent Pancreatic Cancer (preSPARK-1 Study)
Presenter(s)
Y. Chen Sr, Z. Ji, R. Lei, Y. Jiang, B. Qiu, M. Li, J. Li, and J. Wang; Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
Purpose/Objective(s): This study aims to explore the efficacy and safety of stereotactic body radiation therapy (SBRT) with programmed cell death protein-1 (PD-1) inhibitor for locally advanced or locoregionally recurrent pancreatic cancer.
Materials/Methods: A retrospective single-center study was conducted, reviewing medical records of 20 patients diagnosed with locally advanced or locoregional recurrent pancreatic cancer between 2020 and 2024. All participants received SBRT followed by PD-1 blockade every three weeks. Clinical outcomes, including overall response rate (ORR), disease control rate (DCR), local control time (LCT), progression-free survival (PFS), overall survival (OS), adverse events (AEs), and pain relief rate, were statistically analyzed. Responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, while LCT, PFS, and OS were assessed using the Kaplan-Meier method.
Results: The ORR and DCR reached 35.0% and 95.0% respectively. The 1-, and 2-year LCT rates were 93.3%, and 77.8% respectively. The 6-, and 12-month PFS rates were 65.0%, and 29.1% respectively with median PFS of 8.0 months. The 1-, and 2-year OS rates were 86.5%, and 34.6% respectively with median OS of 20.5 months. The pain relief rate was 82.4%. The AEs were generally graded = 2 and well-tolerated.
Conclusion: The SBRT with PD-1 blocker seems to be an effective and safe therapy for locally advanced or locoregionally recurrent pancreatic cancer. Clinical Trial number: NCT06195254.